The NYSE American LLC told Zomedica that it’s no longer in danger of being delisted. The exchange can remove a stock if it closes at less than $1 for more than 30 consecutive days. That’s no longer the case for Zomedica.
Similarly What is Zomedica target price? Stock Price Targets
| High | $1.20 |
|---|---|
| Median | $1.20 |
| Low | $1.20 |
| Average | $1.20 |
| Current Price | $0.35 |
Is Zomedica a good long term investment? ZOM stock is a risky bet in the pet diagnostics field, but it’s affordable and could provide powerful gains in the long-term. Or its downward spiral could continue; that’s a possibility which prospective investors should always consider.
Additionally, Why did Zomedica stock drop?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
Who invested in Zomedica?
Top 10 Owners of Zomedica Corp
| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| The Vanguard Group, Inc. | 4.14% | +181,358 |
| SSgA Funds Management, Inc. | 2.93% | +5,932,371 |
| BlackRock Fund Advisors | 1.19% | -5,530,082 |
| Cambridge Investment Research Adv… | 1.14% | +845 |
Is ZOM stock undervalued? The Bottom Line
However, if you’re a speculative investor, it’s fair to say that 84 cents are an excellent entry point for potential long-term gains beyond 12.6%. Today’s risk-to-reward proposition is about the same as it was in May when I last wrote about Zomedica. To me, ZOM remains undervalued.
Is ZOM shorted? Short Shares Availability
This table shows the number of shares of US:ZOM available to be shorted at a leading prime brokerage. It is not the total number of shares available to short, nor is it the short interest.
How much cash is Zomedica? It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica Corp., formerly known as Zomedica Pharmaceuticals Corp., is based in Ann Arbor, Michigan.
…
Compare ZOM With Other Stocks.
| Zomedica Annual Cash on Hand (Millions of US $) | |
|---|---|
| 2020 | $62 |
| 2019 | $1 |
| 2018 | $2 |
| 2017 | $3 |
What is happening to Zomedica?
Zomedica’s shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner’s delays. Zomedica could rebound once new assays for its Truforma instrument are available.
Why is Zomedica tanking? CEO Robert Cohen said the move was precipitated by « changes at our current distributor that we believe have impacted its ability to market our products effectively. » Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Why is Zomedica stock up?
The big jump came after the veterinary health company provided a sneak peek at its 2021 fourth-quarter and full-year revenue following the market close on Friday. Zomedica reported total revenue in the fourth quarter and full-year 2021 of $4.1 million. The company stated that its gross margin was 73.9%.
What is Truforma Zomedica? Truforma is a blood testing kit for veterinarians. It’s based on bulk acoustic wave (BAW) sensors from Qorvo (NASDAQ:QRVO). The waves are run through pet blood samples to test for adrenal and thyroid diseases.
How much is Truforma cost?
Based on the revision of the average selling price of immunoassay equipment, the average selling price of TRUFORMA was adjusted up to $8,750, and the average number of units sold annually down to 1,140 units annually.
Is Vanguard invested in Zomedica?
Institutional investors has been set as your preferred Vanguard website.
…
1-50 of 4041 | Next>
| Holding | Shares | Market Value |
|---|---|---|
| Zomedica Corp. | 17,423,257 | $6,274,115 |
| Zogenix Inc. | 1,723,411 | $45,256,773 |
| Zoetis Inc. | 13,570,958 | $2,628,016,017 |
Does Vanguard own Zomedica? Vanguard Group Inc reports 0.44% increase in ownership of ZOM / Zomedica Pharmaceuticals Corp. 2022-02-14 – Vanguard Group Inc has filed a 13F-HR form disclosing ownership of 41,635,682 shares of Zomedica Pharmaceuticals Corp. (US:ZOM) with total holdings valued at $12,762,000 USD as of 2021-12-31.
Did BlackRock buy Zom stock? – 13F, 13D, 13G Filings – Fintel.io.
…
BlackRock Inc. reports 29.83% decrease in ownership of ZOM / Zomedica Pharmaceuticals Corp.
| Security | ZOM / Zomedica Pharmaceuticals Corp. |
|---|---|
| Latest Disclosed Value | $ 3,896,000 |
Who is shorting Zom?
Short selling ZOM is an investing strategy that aims to generate trading profit from Zomedica as its price is falling. Zomedica’s stock is trading up $0.02 today. To short Zomedica stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender.
Is Zomedica in a short squeeze? Zomedica Corp (ZOM) Stock Moves To One Month High On Short Squeeze.
How many outstanding shares does Zomedica have?
Zomedica Corp. is a veterinary health company .
…
Compare ZOM With Other Stocks.
| Zomedica Quarterly Shares Outstanding (Millions of Shares) | |
|---|---|
| 2020-09-30 | 551 |
| 2020-06-30 | 215 |
| 2020-03-31 | 118 |
| 2019-12-31 | 106 |
Is Zomedica undervalued? InvestorPlace’s Mark Hake estimates Zomedica (NYSEAMERICAN:ZOM) is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy at current prices.
